Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

EVOLVE-1 trial assesses mTOR inhibitor plus best supportive care in hepatocellular carcinoma

Sep. 7, 2011

Merck & Co. reports discovery of new tachykinin NK1 receptor antagonists

Sep. 7, 2011

Doxazosin versus tizanidine assessed in children with voiding dysfunction

Sep. 7, 2011

SHIFT substudy evaluates ivabradine in patients on background therapy for heart failure

Sep. 7, 2011

Yokukansan ameliorates aspects of two autism spectrum disorders

Sep. 7, 2011

Esmirtazapine may impair day-after driving performance

Sep. 7, 2011

Lu-AA-21004 prevents relapse of major depression in long-term trial

Sep. 6, 2011

Methylene blue beneficial as adjunctive therapy for bipolar disorder

Sep. 6, 2011

Eisai divulges additional phase III data on proprietary AMPA-type glutamate receptor antagonist

Sep. 6, 2011

Data disclosed from ARISTOTLE trial of apixaban vs. warfarin in atrial fibrillation

Sep. 6, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...